Baidu
map

以色列约40%人口完成2剂疫苗接种,公众生活正在全面重启

2021-03-08 JACKZHAO MedSci原创

SCMP

以色列上周日向大流行后的正常状态迈出了又一大步,向已接种疫苗的“绿色通行证”持有人开放餐馆,酒吧和咖啡馆,目前以色列约40%的人口完全接种了疫苗,成为接种率最高的国家。根据《南华早报》与脸书上发布的一段视频,总理本杰明·内塔尼亚胡在耶路撒冷的一家咖啡馆切成糕点时宣布:“我们正在正常生活。”

以色列于12月启动了全国疫苗接种运动,已向其大约900万人中的370万人推荐了两次接种的辉瑞/ BioNTech疫苗。近500万人接种了第一针。以色列的疫苗接种运动已经显示出明显的成功迹象:如魏茨曼研究所(预印本)所做的初步分析所示,感染数量正在大幅下降,尤其是在60岁以上人群中。 在这个年龄组中,第二剂后感染减少了56%,住院减少了42%,COVID-19死亡减少了35%。

拥有900万人口的国家能够获得如此大量的疫苗,这一事实与以色列与制造商签订的合同中商定的特殊条款有关。 以色列与欧盟不同协议不同。根据协议,以色列为BioNTech-Pfizer疫苗的每剂疫苗支付的费用比欧盟高得多,据报道每剂疫苗约为23欧元(28美元),而欧盟为12欧元。

此外,以色列政府保留产品责任。 另一方面,欧盟非常希望BioNTech-Pfizer继续对产品的安全性负责。最重要的是,以色列政府同意向疫苗生产商每周提供疫苗接种数据。这包括感染和疫苗接种数量,以及年龄和性别等患者人口统计信息。 以色列官员说,这些数据是匿名发送给辉瑞公司的。得益于以色列的数字化医疗保健系统,制药公司不仅可以快速,可靠地接收数据,而且最重要的是,与其他任何研究相比,它们获得的数据要多得多。 对于制药公司来说,这是宝贵的信息来源。作为回报,制造商承诺向以色列提供疫苗,直到实现95%的人口免疫为止。

https://www.medrxiv.org/content/10.1101/2021.02.08.21251325v1.full.pdf

该国上个月启动了绿色通行证计划,允许控制数量的有充分疫苗接种证明的人(或从COVID-19中恢复过来的人)进入体育馆,游泳池和其他场所。但是,人们对昨天重新开放的计划表示高度期待,因为它标志着服务的恢复,涉及许多以色列人的日常生活。

现在允许餐馆恢复室内用餐,最多容纳75%的容量,上限为100人,并且桌子相距2米。持有绿色通行证的人现在也可以在酒吧喝一杯,但还不能与坐在他们旁边凳子上的陌生人聊天,规则是顾客之间必须有空座位,除非他们住在一起。在露台上进食和饮水不需要绿色通行证。

大量学生,其中许多人已经离开教室几个月了,他们也将在本周开始重返学校,而酒店活动大厅,运动场馆和礼拜场所将重新开放给持有绿色通行证的人,并限制了学生人数。在长达数周的机场关闭期间滞留在国外的以色列人本周也将被允许越来越多地返回家园,从周日允许1,000名入境者开始。

内塔尼亚胡(Netanyahu)在两周内将面临艰难的连任之战,他将以色列强劲的疫苗接种运动置于其竞选活动的中心。尽管许多国家一直在努力确保疫苗供应,但内塔尼亚胡政府的库存仍然充裕,这在很大程度上要归功于与辉瑞公司达成的关于分享该产品影响的医学数据的安排。

这位自2009年上台的总理曾表示,他希望以色列在本月底之前为整个16岁以上的人群接种疫苗,希望该国经济能够在3月27日逾越节假期之前及时完全重新开放。

尽管以色列的疫苗接种速度仍然是世界上最快的,但这个犹太国家面临着广泛的呼吁,包括来自联合国的呼吁,以确保对生活在占领下的西岸的巴勒斯坦人以及在以色列封锁的加沙地带进行接种。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1257948, encodeId=c83e125e9482c, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Mar 10 09:25:50 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946895, encodeId=78cc946895a7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 09 20:21:29 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946772, encodeId=3251946e72d8, content=40%以色列人民接种疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 09 12:53:31 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946584, encodeId=f1f29465843d, content=效率很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/ae7665075c184c23a6e784e6269320b0/c581d11218024bf1af694b1df0036472.jpg, createdBy=75095431701, createdName=ms5000000050796128, createdTime=Mon Mar 08 22:15:40 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946569, encodeId=fbeb94656951, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210308/ee92791efc274c3fa0b59c0ced8592b9/e0153faceb6943e38173dc65f2b4956e.jpg, createdBy=8ebe1507172, createdName=348511787, createdTime=Mon Mar 08 21:43:54 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946502, encodeId=1d1b946502b6, content=我们已经生活正常很久了😂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Mon Mar 08 18:40:49 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1257948, encodeId=c83e125e9482c, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Mar 10 09:25:50 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946895, encodeId=78cc946895a7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 09 20:21:29 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946772, encodeId=3251946e72d8, content=40%以色列人民接种疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 09 12:53:31 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946584, encodeId=f1f29465843d, content=效率很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/ae7665075c184c23a6e784e6269320b0/c581d11218024bf1af694b1df0036472.jpg, createdBy=75095431701, createdName=ms5000000050796128, createdTime=Mon Mar 08 22:15:40 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946569, encodeId=fbeb94656951, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210308/ee92791efc274c3fa0b59c0ced8592b9/e0153faceb6943e38173dc65f2b4956e.jpg, createdBy=8ebe1507172, createdName=348511787, createdTime=Mon Mar 08 21:43:54 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946502, encodeId=1d1b946502b6, content=我们已经生活正常很久了😂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Mon Mar 08 18:40:49 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-09 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1257948, encodeId=c83e125e9482c, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Mar 10 09:25:50 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946895, encodeId=78cc946895a7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 09 20:21:29 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946772, encodeId=3251946e72d8, content=40%以色列人民接种疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 09 12:53:31 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946584, encodeId=f1f29465843d, content=效率很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/ae7665075c184c23a6e784e6269320b0/c581d11218024bf1af694b1df0036472.jpg, createdBy=75095431701, createdName=ms5000000050796128, createdTime=Mon Mar 08 22:15:40 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946569, encodeId=fbeb94656951, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210308/ee92791efc274c3fa0b59c0ced8592b9/e0153faceb6943e38173dc65f2b4956e.jpg, createdBy=8ebe1507172, createdName=348511787, createdTime=Mon Mar 08 21:43:54 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946502, encodeId=1d1b946502b6, content=我们已经生活正常很久了😂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Mon Mar 08 18:40:49 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-09 科研科研科研

    40%以色列人民接种疫苗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1257948, encodeId=c83e125e9482c, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Mar 10 09:25:50 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946895, encodeId=78cc946895a7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 09 20:21:29 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946772, encodeId=3251946e72d8, content=40%以色列人民接种疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 09 12:53:31 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946584, encodeId=f1f29465843d, content=效率很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/ae7665075c184c23a6e784e6269320b0/c581d11218024bf1af694b1df0036472.jpg, createdBy=75095431701, createdName=ms5000000050796128, createdTime=Mon Mar 08 22:15:40 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946569, encodeId=fbeb94656951, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210308/ee92791efc274c3fa0b59c0ced8592b9/e0153faceb6943e38173dc65f2b4956e.jpg, createdBy=8ebe1507172, createdName=348511787, createdTime=Mon Mar 08 21:43:54 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946502, encodeId=1d1b946502b6, content=我们已经生活正常很久了😂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Mon Mar 08 18:40:49 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 ms5000000050796128

    效率很高

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1257948, encodeId=c83e125e9482c, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Mar 10 09:25:50 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946895, encodeId=78cc946895a7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 09 20:21:29 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946772, encodeId=3251946e72d8, content=40%以色列人民接种疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 09 12:53:31 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946584, encodeId=f1f29465843d, content=效率很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/ae7665075c184c23a6e784e6269320b0/c581d11218024bf1af694b1df0036472.jpg, createdBy=75095431701, createdName=ms5000000050796128, createdTime=Mon Mar 08 22:15:40 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946569, encodeId=fbeb94656951, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210308/ee92791efc274c3fa0b59c0ced8592b9/e0153faceb6943e38173dc65f2b4956e.jpg, createdBy=8ebe1507172, createdName=348511787, createdTime=Mon Mar 08 21:43:54 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946502, encodeId=1d1b946502b6, content=我们已经生活正常很久了😂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Mon Mar 08 18:40:49 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 348511787

    很好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1257948, encodeId=c83e125e9482c, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Mar 10 09:25:50 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946895, encodeId=78cc946895a7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Mar 09 20:21:29 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946772, encodeId=3251946e72d8, content=40%以色列人民接种疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 09 12:53:31 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946584, encodeId=f1f29465843d, content=效率很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/ae7665075c184c23a6e784e6269320b0/c581d11218024bf1af694b1df0036472.jpg, createdBy=75095431701, createdName=ms5000000050796128, createdTime=Mon Mar 08 22:15:40 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946569, encodeId=fbeb94656951, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210308/ee92791efc274c3fa0b59c0ced8592b9/e0153faceb6943e38173dc65f2b4956e.jpg, createdBy=8ebe1507172, createdName=348511787, createdTime=Mon Mar 08 21:43:54 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946502, encodeId=1d1b946502b6, content=我们已经生活正常很久了😂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Mon Mar 08 18:40:49 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 神盾医疗局局长Jack

    我们已经生活正常很久了😂

    0

相关资讯

以色列医院完成首例心衰治疗装置人体植入手术

以色列海法Rambam医院发布消息称,该院专家最近完成了第一例CORolla装置植入手术,该装置由以色列初创公司CorAssist研发,植入患者是一位72岁的舒张性心衰患者。目前世界上对于舒展性心衰并无有效治疗方案。CorAssist公司研发的CORolla装置通过微创手术可在不停跳情况下植入患者左室内,该弹性装置通过对室壁直接扩张力可有效改善心脏舒张功能,增加舒张期血液充盈量,改善心衰症状。植入

揭秘:以色列应急医疗“王牌军”是如何炼成的

提高医疗专业水准的同时不断依据现场情况锤炼应急反应能力,是培养应急医疗“王牌军”的不二法宝。

以色列健康信息化经验探究

去年,应以色列卫生部邀请,国家卫生计生委规划司牵头组织有关单位,赴以色列参加“中国-以色列数字健康合作”专题研讨会,围绕信息交换共享、远程医疗应用、大数据发展和隐私保护等方面开展学习交流。以色列在医疗卫生体系和数字健康建设方面的有益探索,对于我国深化医药卫生体制改革,以信息化和大数据助推健康中国建设,具有重要的借鉴意义。

以色列全新真实世界研究证实BioNTech疫苗在首剂后有效率为85%,力证推迟接种二剂

以色列最新真实世界研究证实BioNTech/辉瑞疫苗在首剂后有效率为85%,力证推迟第二剂疫苗的覆盖率将大大提高。

NEJM:BNT162b2 mRNA疫苗在以色列大规模接种后的有效性评估

通过以色列全国的大规模疫苗接种,BNT162b2 mRNA疫苗的有效性得到了充分验证

以色列称研制新冠病毒疫苗取得重大进展,正准备进行动物实验

以色列总理办公室3月31日发表声明说,以色列生物研究所在研制抗新冠病毒疫苗方面取得进展,将很快进行动物实验。

Baidu
map
Baidu
map
Baidu
map